64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
复制标题
DOI：
10.2967/jnumed.112.118612
复制
发表时间：
2013-11-01
影响因子：
9.3
通讯作者：
Fujiwara, Yasuhiro
中科院分区：
文献类型：
--
作者：
Tamura, Kenji;Kurihara, Hiroaki;Fujiwara, Yasuhiro
本研究的目的是确定cu -64- dota -曲妥珠单抗在人体内的安全性、分布、内剂量学和初始人表皮生长因子受体2 （HER2）阳性肿瘤图像。方法：对6例原发性或转移性her2阳性乳腺癌患者在注射约130 MBq探针cu -64- dota -曲妥珠单抗后1、24和48小时进行PET检查。从6例患者的血液、尿液和正常组织样本中收集放射性数据，并评估探针的多器官生物分布和内剂量学。收集所有患者在给予cu -64- dota -曲妥珠单抗后和1周随访期间的安全性数据。结果：根据我们的研究结果，评估cu -64- dota -曲妥珠单抗被肿瘤摄取的最佳时机是注射后48 h。cu -64- dota -曲妥珠单抗PET期间的辐射暴露与常规F-18-FDG PET期间的辐射暴露相当。血液中的放射性较高，但正常组织中cu -64- dota -曲妥珠单抗的摄取较低。2例患者，cu -64- dota -曲妥珠单抗PET显示脑转移，表明血脑屏障破坏。在3例患者中，cu -64- dota -曲妥珠单抗PET成像也在CT最初发现的病变部位发现了原发性乳腺肿瘤。结论：本研究结果表明，cu -64- dota -曲妥珠单抗PET鉴别原发性和转移性乳腺癌患者her2阳性病变是可行的。剂量学和药理学安全性结果在PET成像所需的剂量下是可接受的。
The purpose of this study was to determine the safety, distribution, internal dosimetry, and initial human epidermal growth factor receptor 2 (HER2)-positive tumor images of Cu-64-DOTA-trastuzumab in humans. Methods: PET was performed on 6 patients with primary or metastatic HER2-positive breast cancer at 1, 24, and 48 h after injection of approximately 130 MBq of the probe Cu-64-DOTA-trastuzumab. Radioactivity data were collected from the blood, urine, and normal-tissue samples of these 6 patients, and the multiorgan biodistribution and internal dosimetry of the probe were evaluated. Safety data were collected for all the patients after the administration of Cu-64-DOTA-trastuzumab and during the 1-wk follow-up period. Results: According to our results, the best timing for the assessment of Cu-64-DOTA-trastuzumab uptake by the tumor was 48 h after injection. Radiation exposure during Cu-64-DOTA-trastuzumab PET was equivalent to that during conventional F-18-FDG PET. The radioactivity in the blood was high, but uptake of Cu-64-DOTA-trastuzumab in normal tissues was low. In 2 patients, Cu-64-DOTA-trastuzumab PET showed brain metastases, indicative of blood-brain barrier disruptions. In 3 patients, Cu-64-DOTA-trastuzumab PET imaging also revealed primary breast tumors at the lesion sites initially identified by CT. Conclusion: The findings of this study indicated that Cu-64-DOTA-trastuzumab PET is feasible for the identification of HER2-positive lesions in patients with primary and metastatic breast cancer. The dosimetry and pharmacologic safety results were acceptable at the dose required for adequate PET imaging.